Translational Lung Cancer Research

Article	Citations
Radiomics and artificial intelligence in lung cancer screening	96
A narrative review of tumor-associated macrophages in lung cancer: regulation of macrophage polarization and therapeutic implications	96
Epidemiology of stage III lung cancer: frequency, diagnostic characteristics, and survival	71
Tumor-associated macrophages secret exosomal miR-155 and miR-196a-5p to promote metastasis of non-small-cell lung cancer	56
Targeting histone deacetylase enhances the therapeutic effect of Erastin-induced ferroptosis in EGFR-activating mutant lung adenocarcinoma	51
Circulating tumor DNA predicts neoadjuvant immunotherapy efficacy and recurrence-free survival in surgical non-small cell lung cancer patients	48
Expert consensus on neoadjuvant immunotherapy for non-small cell lung cancer	47
Lung cancer screening and smoking cessation efforts	46
Current progress and mechanisms of bone metastasis in lung cancer: a narrative review	43
Artificial intelligence for detection and characterization of pulmonary nodules in lung cancer CT screening: ready for practice?	43
Transbronchial microwave ablation of lung nodules with electromagnetic navigation bronchoscopy guidance—a novel technique and initial experience with 30 cases	43
Emerging and multifaceted role of neutrophils in lung cancer	42
Neoadjuvant immunotherapy or chemoimmunotherapy in non-small cell lung cancer: a systematic review and meta-analysis	38
Preoperative peripheral blood neutrophil-to-lymphocyte ratios (NLR) and platelet-to-lymphocyte ratio (PLR) related nomograms predict the survival of patients with limited-stage small-cell lung cancer	38
Exosomal miR-375-3p breaks vascular barrier and promotes small cell lung cancer metastasis by targeting claudin-1	37
A narrative review of MET inhibitors in non-small cell lung cancer with MET exon 14 skipping mutations	37
Thermal ablation in non-small cell lung cancer: a review of treatment modalities and the evidence for combination with immune checkpoint inhibitors	36
Lung cancer screening in Europe: where are we in 2021?	33
Pleural biomarkers in diagnostics of malignant pleural effusion: a narrative review	33
Role of next generation sequencing-based liquid biopsy in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors: impact of STK11, KRAS and TP53 mutations and co-mutati	32
Expert consensus on resection of chest wall tumors and chest wall reconstruction	32
KRASG12C/TP53 co-mutations identify long-term responders to first line palliative treatment with pembrolizumab monotherapy in PD-L1 high (≥50%) lung adenocarcinoma	32
tsRNA-5001a promotes proliferation of lung adenocarcinoma cells and is associated with postoperative recurrence in lung adenocarcinoma patients	32
Exploration of radiation-induced lung injury, from mechanism to treatment: a narrative review	31
Metformin reverses chemoresistance in non-small cell lung cancer via accelerating ubiquitination-mediated degradation of Nrf2	30

Neoadjuvant programmed cell death protein 1 inhibitors combined with chemotherapy in resectable non-small cell lung cancer: an open-label, multicenter, single-arm study	29
High indoleamine-2,3-dioxygenase 1 (IDO) activity is linked to primary resistance to immunotherapy in non-small cell lung cancer (NSCLC)	29
Is there any place for PD-1/CTLA-4 inhibitors combination in the first-line treatment of advanced NSCLC?—a trial-level meta-analysis in PD-L1 selected subgroups	28
CircP4HB regulates ferroptosis via SLC7A11-mediated glutathione synthesis in lung adenocarcinoma	28
Molecular biomarkers in early stage lung cancer	27
Circulating tumor cells can predict the prognosis of patients with non-small cell lung cancer after resection: a retrospective study	26
Emerging oncogenic fusions other than ALK, ROS1, RET, and NTRK in NSCLC and the role of fusions as resistance mechanisms to targeted therapy	26
Cancer cachexia syndrome and clinical outcome in patients with metastatic non-small cell lung cancer treated with PD-1/PD-L1 inhibitors: results from a prospective, observational study	25
Circ-AASDH functions as the progression of early stage lung adenocarcinoma by targeting miR-140-3p to activate E2F7 expression	25
Latest CT technologies in lung cancer screening: protocols and radiation dose reduction	25
First-line immunotherapy in non-small cell lung cancer patients with poor performance status: a systematic review and meta-analysis	25
Emerging biomarkers for neoadjuvant immune checkpoint inhibitors in operable non-small cell lung cancer	25
Efficacy of docetaxel plus ramucirumab as palliative second-line therapy following first-line chemotherapy plus immune-checkpoint-inhibitor combination treatment in patients with non-small cell lung c	25
Prognostic significance of the neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio for advanced non-small cell lung cancer patients with high PD-L1 tumor expression receiving pembrolizumab	25
PD-L1 detection on circulating tumor-derived extracellular vesicles (T-EVs) from patients with lung cancer	25
Deubiquitinase USP5 promotes non-small cell lung cancer cell proliferation by stabilizing cyclin D1	25
Impact of chronic obstructive pulmonary disease on immune checkpoint inhibitor efficacy in advanced lung cancer and the potential prognostic factors	24
circFBXW7 attenuates malignant progression in lung adenocarcinoma by sponging miR-942-5p	24
Narrative review of molecular pathways of kinase fusions and diagnostic approaches for their detection in non-small cell lung carcinomas	23
B cells in lung cancer—not just a bystander cell: a literature review	23
Radiotherapy programs neutrophils to an antitumor phenotype by inducing mesenchymal-epithelial transition	23
Implementation of lung cancer screening: what are the main issues?	23
A signature of estimate-stromal-immune score-based genes associated with the prognosis of lung adenocarcinoma	23
A machine learning-based prediction of the micropapillary/solid growth pattern in invasive lung adenocarcinoma with radiomics	22
Impact of an enhanced recovery after surgery pathway on thoracoscopic lobectomy outcomes in non-small cell lung cancer patients: a propensity score-matched study	22
SLFN11 biomarker status predicts response to lurbinectedin as a single agent and in combination with ATR inhibition in small cell lung cancer	22
Exon 20 YVMA insertion is associated with high incidence of brain metastasis and inferior outcome of chemotherapy in advanced non-small cell lung cancer patients with HER2 kinase domain mutations	22
Immune checkpoint inhibitors in oncogene-addicted non-small cell lung cancer: a systematic review and meta-analysis	21
Prognostic implications of cellular senescence in resected non-small cell lung cancer	21
Decade in review: a new era for RET-rearranged lung cancers	21
MRI radiomic signature predicts intracranial progression-free survival in patients with brain metastases of ALK-positive non-small cell lung cancer	21
Sleeve lobectomy after neoadjuvant chemoimmunotherapy/chemotherapy for local advanced non-small cell lung cancer	21
Current and future biomarkers for outcomes with immunotherapy in non-small cell lung cancer	20
Feasibility of implementing a national lung cancer screening program: Interim results from the Korean Lung Cancer Screening Project (K-LUCAS)	20
Low-level expression of necroptosis factors indicates a poor prognosis of the squamous cell carcinoma subtype of non-small-cell lung cancer	20
cGAS-STING pathway expression as a prognostic tool in NSCLC	20
Phase 1/2 study of alectinib in RET-rearranged previously-treated non-small cell lung cancer (ALL-RET)	19
Combining radiotherapy with targeted therapies in non-small cell lung cancer: focus on anti-EGFR, anti-ALK and anti-angiogenic agents	19
Let-7b-3p inhibits tumor growth and metastasis by targeting the BRF2-mediated MAPK/ERK pathway in human lung adenocarcinoma	19
A fully automated assay to detect the expression of pan-cytokeratins and of EML4-ALK fusion protein in circulating tumour cells (CTCs) predicts outcome of non-small cell lung cancer (NSCLC) patients	19
Predictive values of genomic variation, tumor mutational burden, and PD-L1 expression in advanced lung squamous cell carcinoma treated with immunotherapy	19
Identification of serum biomarkers to predict pemetrexed/platinum chemotherapy efficacy for advanced lung adenocarcinoma patients by data-independent acquisition (DIA) mass spectrometry analysis with	19
Neoadjuvant chemoimmunotherapy in resectable stage IIIA/IIIB non-small cell lung cancer	19
Systemic immune-inflammation index is a stage-dependent prognostic factor in patients with operable non-small cell lung cancer	19
Pulmonary function changes after thoracoscopic lobectomy versus intentional thoracoscopic segmentectomy for early-stage non-small cell lung cancer	19
Safety of lorlatinib following alectinib-induced pneumonitis in two patients with ALK-rearranged non-small cell lung cancer: a case series	19
Association between dietary sodium, potassium intake and lung cancer risk: evidence from the prostate, lung, colorectal and ovarian cancer screening trial and the Women’s Health Initiative	19
Genomic profiling of extracellular vesicle-derived DNA from bronchoalveolar lavage fluid of patients with lung adenocarcinoma	18
Prognostic impact of PD-1 and PD-L1 expression in malignant pleural mesothelioma: an international multicenter study	18
Risk factors for immune checkpoint inhibitor-related pneumonitis in non-small cell lung cancer	18

Combing stereotactic body radiotherapy with checkpoint inhibitors after oligoprogression in advanced non-small cell lung cancer	18
Participation in lung cancer screening	18
Correlation of peripheral blood biomarkers with clinical outcomes in NSCLC patients with high PD-L1 expression treated with pembrolizumab	18
Clinicopathologic characteristics and diagnostic methods of RET rearrangement in Chinese non-small cell lung cancer patients	18
Whole exome sequencing (WES) analysis of transformed small cell lung cancer (SCLC) from lung adenocarcinoma (LUAD)	18
Added benefits of early detection of other diseases on low-dose CT screening	18
Role of lymphatic endothelial cells in the tumor microenvironment—a narrative review of recent advances	18
Concurrent use of metformin enhances the efficacy of EGFR-TKIs in patients with advanced EGFR-mutant non-small cell lung cancer—an option for overcoming EGFR-TKI resistance	17
A large real-world cohort study of examined lymph node standards for adequate nodal staging in early non-small cell lung cancer	17
Challenges in the target volume definition of lung cancer radiotherapy	17
Mediastinal staging for non-small cell lung cancer	17
EGFR variant allele frequency predicts EGFR-TKI efficacy in lung adenocarcinoma: a multicenter study	17
Salvage surgery after definitive chemoradiotherapy for patients with non-small cell lung cancer	17
A nomogram for predicting the risk of lymph node metastasis in T1–2 non-small-cell lung cancer based on PET/CT and clinical characteristics	17
Stage III N2 non-small cell lung cancer treatment: decision-making among surgeons and radiation oncologists	17
Deep learning for predicting immunotherapeutic efficacy in advanced non-small cell lung cancer patients: a retrospective study combining progression-free survival risk and overall survival risk	17
Prognostic value of baseline and change in neutrophil-to-lymphocyte ratio for survival in advanced non-small cell lung cancer patients with poor performance status receiving PD-1 inhibitors	16
Dose and fractionation schedules in radiotherapy for non-small cell lung cancer	16
Immune-related adverse event profile of combination treatment of PD-(L)1 checkpoint inhibitors and bevacizumab in non-small cell lung cancer patients: data from the FDA adverse event reporting system	16
Pembrolizumab-induced myocarditis in a patient with malignant mesothelioma: plasma exchange as a successful emerging therapy—case report	16
M5C regulator-mediated methylation modification patterns and tumor microenvironment infiltration characterization in lung adenocarcinoma	16
Triptolide inhibits epithelial-mesenchymal transition phenotype through the p70S6k/GSK3/β-catenin signaling pathway in taxol-resistant human lung adenocarcinoma	16
The predictive utility of patient-reported outcomes and performance status for survival in metastatic lung cancer patients treated with chemoimmunotherapy	16
Anlotinib combined with gefitinib can significantly improve the proliferation of epidermal growth factor receptor-mutant advanced non-small cell lung cancer in vitro and in vivo	15
How to select the best upfront therapy for metastatic disease? Focus on ALK-rearranged non-small cell lung cancer (NSCLC)	15
Hyperprogression under immunotherapy: a new form of immunotherapy response?—a narrative literature review	15
Can autoantibody tests enhance lung cancer screening?—an evaluation of EarlyCDT®-Lung in context of the German Lung Cancer Screening Intervention Trial (LUSI)	15
Tumor immune microenvironment in epidermal growth factor receptor-mutated non-small cell lung cancer before and after epidermal growth factor receptor tyrosine kinase inhibitor treatment: a narrative	15
TP53 co-mutations as an independent prognostic factor in 2nd and further line therapy—EGFR mutated non-small cell lung cancer IV patients treated with osimertinib	15
Correlations between peripheral blood biomarkers and clinical outcomes in advanced non-small cell lung cancer patients who received immunotherapy-based treatments	15
Artificial intelligence-based analysis for immunohistochemistry staining of immune checkpoints to predict resected non-small cell lung cancer survival and relapse	15
Surgery after neoadjuvant immunotherapy in patients with resectable non-small cell lung cancer	15
BCKDK alters the metabolism of non-small cell lung cancer	15
Resistance to anaplastic lymphoma kinase inhibitors: knowing the enemy is half the battle won	15
Impact of tumor programmed death ligand-1 expression on osimertinib efficacy in untreated EGFR-mutated advanced non-small cell lung cancer: a prospective observational study	14
Cholesterol synthesis disruption combined with a molecule-targeted drug is a promising metabolic therapy for EGFR mutant non-small cell lung cancer	14
Current and future applications of liquid biopsy in non-small-cell lung cancer—a narrative review	14
Integrating immune checkpoint inhibitors and targeted therapies in the treatment of early stage non-small cell lung cancer: a narrative review	14
Increased plasma levels of damage-associated molecular patterns during systemic anticancer therapy in patients with advanced lung cancer	14
Immunotherapy beyond progression in patients with advanced non-small cell lung cancer	14
High discrepancy in thrombotic events in non-small cell lung cancer patients with different genomic alterations	14
Detection and quantification of EGFR T790M mutation in liquid biopsies by droplet digital PCR	14
Lung function impairment in the German Lung Cancer Screening Intervention Study (LUSI): prevalence, symptoms, and associations with lung cancer risk, tumor histology and all-cause mortality	14
Comparison of perioperative outcomes of robotic-assisted versus video-assisted thoracoscopic right upper lobectomy in non-small cell lung cancer	14
Stereotactic radiotherapy for early stage non-small cell lung cancer: current standards and ongoing research	14
Safety and efficacy of retreatment with immune checkpoint inhibitors in non-small cell lung cancer: a systematic review and meta-analysis	14
Rapid genomic profiling of circulating tumor DNA in non-small cell lung cancer using Oncomine Precision Assay with GenexusTM integrated sequencer	14
Prediction of future imagery of lung nodule as growth modeling with follow-up computed tomography scans using deep learning: a retrospective cohort study	14
The role of the surgeon in the management of oligometastatic non-small cell lung cancer: a literature review	14
Strategies to overcome resistance to ALK inhibitors in non-small cell lung cancer: a narrative review	14
Role of radiomics in predicting lung cancer spread through air spaces in a heterogeneous dataset	14
In small cell lung cancer patients treated with RRx-001, a downregulator of CD47, decreased expression of PD-L1 on circulating tumor cells significantly correlates with clinical benefit	14
Programmed death-ligand 1 expression level as a predictor of EGFR tyrosine kinase inhibitor efficacy in lung adenocarcinoma	14
Electromagnetic bronchoscopy guided microwave ablation for early stage lung cancer presenting as ground glass nodule	14
Different prognostic implications of hepatic metastasis according to front-line treatment in non-small cell lung cancer: a real-world retrospective study	13
International consensus on radiotherapy in metastatic non-small cell lung cancer	13
The landscape of cancer cachexia in advanced non-small cell lung cancer: a narrative review	13
NLRP3 activation in tumor-associated macrophages enhances lung metastasis of pancreatic ductal adenocarcinoma	13
Smoking burden, MPOWER, future tobacco control and real-world challenges in China: reflections on the WHO report on the global tobacco epidemic 2021	13
Expert consensus on perioperative immunotherapy for local advanced non-small cell lung cancer	13
Inhaled corticosteroids and risk of lung cancer among chronic obstructive pulmonary disease patients: a comprehensive analysis of nine prospective cohorts	13
Thoracic radiotherapy in small cell lung cancer—a narrative review	13
Identification of GPX4 as a therapeutic target for lung adenocarcinoma after EGFR-TKI resistance	13
A prognostic nomogram for lung adenocarcinoma based on immune-infiltrating Treg-related genes: from bench to bedside	13
One carbon metabolism in human lung cancer	13
Outcomes for localized treatment of large cell neuroendocrine carcinoma of the lung in the United States	13
Identifying optimal candidates for primary tumor resection among metastatic non-small cell lung cancer patients: a population-based predictive model	13
TIPE3 promotes non-small cell lung cancer progression via the protein kinase B/extracellular signal-regulated kinase 1/2-glycogen synthase kinase 3β-β-catenin/Snail axis	13
The radiologist’s role in lung cancer screening	12
Comprehensive analysis of blood-based biomarkers for predicting immunotherapy benefits in patients with advanced non-small cell lung cancer	12
Clinicopathologic and molecular characteristics of EGFR-mutant lung adenocarcinomas that transform to small cell lung cancer after TKI therapy	12
The landscape of immune checkpoints expression in non-small cell lung cancer: a narrative review	12
Causal effects of genetically determined metabolites on cancers included lung, breast, ovarian cancer, and glioma: a Mendelian randomization study	12
EGFR exon 20 insertion mutations and ERBB2 mutations in lung cancer: a narrative review on approved targeted therapies from oral kinase inhibitors to antibody-drug conjugates	12
A uniportal right upper lobectomy by three-arm robotic-assisted thoracoscopic surgery using the da Vinci (Xi) Surgical System in the treatment of early-stage lung cancer	12
Lung cancer screening: targeting the hard to reach—a review	12
Robotic-assisted thoracic surgery reduces perioperative complications and achieves a similar long-term survival profile as posterolateral thoracotomy in clinical N2 stage non-small cell lung cancer pa	12
The effectiveness of three-dimensional reconstruction in the localization of multiple nodules in lung specimens: a prospective cohort study	12
Earlier extracranial progression and shorter survival in ALK- rearranged lung cancer with positive liquid rebiopsies	12
Consecutive severe immune-related adverse events after PD-1 inhibitor induction and surgery in locally advanced non-small cell lung cancer: a case report	12

Identifying the prognostic significance of B3GNT3 with PD-L1 expression in lung adenocarcinoma	12
The person behind the nodule: a narrative review of the psychological impact of lung cancer screening	12
Tumour motion management in lung cancer: a narrative review	12
Pembrolizumab monotherapy or combination therapy for bone metastases in advanced non-small cell lung cancer: a real-world retrospective study	12
Ongoing challenges in implementation of lung cancer screening	12
Managing of screening-detected sub-solid nodules—a European perspective	12
Multimodal therapy of epithelioid pleural mesothelioma: improved survival by changing the surgical treatment approach	12
Evaluation of PD-L1 expression on circulating tumour cells in small-cell lung cancer	12
International expert consensus on immunotherapy for early-stage non-small cell lung cancer	12
The protective effects of granulocyte-macrophage colony-stimulating factor against radiation-induced lung injury	12
Increased detection of circulating tumor DNA by short fragment enrichment	12
Assessing the association of diabetes with lung cancer risk	12
Public opinion on implementing the National Lung Cancer Screening Program in Korea	12
Circulating tumor cell methylation profiles reveal the classification and evolution of non-small cell lung cancer	11
A cohort study of the efficacy and safety of immune checkpoint inhibitors plus anlotinib versus immune checkpoint inhibitors alone as the treatment of advanced non-small cell lung cancer in the real w	11
Sleeve resection after neoadjuvant chemoimmunotherapy in the treatment of locally advanced non-small cell lung cancer	11
A cuproptosis-related long non-coding RNA signature to predict the prognosis and immune microenvironment characterization for lung adenocarcinoma	11
Impact of docetaxel plus ramucirumab on metastatic site in previously treated patients with non-small cell lung cancer: a multicenter retrospective study	11
Smoking signature is superior to programmed death-ligand 1 expression in predicting pathological response to neoadjuvant immunotherapy in lung cancer patients	11
Elevated expression of miR-494-3p is associated with resistance to osimertinib in EGFR T790M-positive non-small cell lung cancer	11
Overcoming TKI resistance in fusion-driven NSCLC: new generation inhibitors and rationale for combination strategies	11
Concomitant mutation status of ALK-rearranged non-small cell lung cancers and its prognostic impact on patients treated with crizotinib	11
Real-world outcomes of chemo-antiangiogenesis versus chemo-immunotherapy combinations in EGFR-mutant advanced non-small cell lung cancer patients after failure of EGFR-TKI therapy	11
Safety and efficacy of nivolumab plus recombinant human endostatin in previously treated advanced non-small-cell lung cancer	11
Immune checkpoint inhibitor (ICI)-based treatment beyond progression with prior immunotherapy in patients with stage IV non-small cell lung cancer: a retrospective study	11
A narrative review of invasive diagnostics and treatment of early lung cancer	11
Increase in tumour PD-L1 expression in non-small cell lung cancer following bronchoscopic thermal vapour ablation	11
Role of the epithelial-mesenchymal transition-related circular RNA, circ-10720, in non-small-cell lung cancer	11
A narrative review of primary research endpoints of neoadjuvant therapy for lung cancer: past, present and future	11
A multidisciplinary approach to the work up and management of pulmonary carcinoid tumors and DIPNECH: a narrative review	11
Clinical features and prognostic factors of combined small cell lung cancer: development and validation of a nomogram based on the SEER database	11
Tumor PD-L1 expression is associated with outcomes in stage III non-small cell lung cancer (NSCLC) patients treated with consolidation durvalumab	11
Application of indocyanine green injection guided by electromagnetic navigation bronchoscopy in localization of pulmonary nodules	11
Development and validation of the artificial intelligence (AI)-based diagnostic model for bronchial lumen identification	11
Cytokine release syndrome in a patient with non-small cell lung cancer on ipilimumab and nivolumab maintenance therapy after vaccination with the mRNA-1273 vaccine: a case report	11
Osimertinib in non-small cell lung cancer with uncommon EGFR-mutations: a post-hoc subgroup analysis with pooled data from two phase II clinical trials	11
A narrative review on tumor microenvironment in oligometastatic and oligoprogressive non-small cell lung cancer: a lot remains to be done	11
Expert consensus on indocyanine green fluorescence imaging for thoracoscopic lung resection (The Version 2022)	11
Consistency of recommendations for the diagnosis and treatment of non-small cell lung cancer: a systematic review	11
The oncogenic landscape of the idiopathic pulmonary fibrosis: a narrative review	11
Should resection extent be decided by total lesion size or solid component size in ground glass opacity-containing lung adenocarcinomas?	11
Preoperative computer tomography-guided indocyanine green injection is associated with successful localization of small pulmonary nodules	11
Clinical features and prognosis of resectable pulmonary primary invasive mucinous adenocarcinoma	11
Immunotherapy in malignant pleural mesothelioma: a review of literature data	11
Clinical types of checkpoint inhibitor-related pneumonitis in lung cancer patients: a multicenter experience	11
Plasma cell-free DNA and circulating tumor cells as prognostic biomarkers in small cell lung cancer patients	11
Hsa_circ_0006571 promotes spinal metastasis through sponging microRNA-138 to regulate sirtuin 1 expression in lung adenocarcinoma	11
Pre-radiotherapy lymphocyte count and platelet-to-lymphocyte ratio may improve survival prediction beyond clinical factors in limited stage small cell lung cancer: model development and validation	10
Neoadjuvant treatment of stage IIIA-N2 in EGFR-Mutant/ALK-rearranged non-small cell lung cancer	10
Efficacy and safety of amrubicin therapy after chemoimmunotherapy in small cell lung cancer patients	10
Central nervous system metastases and oligoprogression during treatment with tyrosine kinase inhibitors in oncogene-addicted non-small cell lung cancer: how to treat and when?	10
An immune-related gene expression signature predicts brain metastasis in lung adenocarcinoma patients after surgery: gene expression profile and immunohistochemical analyses	10
Association of hepatitis B virus infection status with outcomes of non-small cell lung cancer patients undergoing anti-PD-1/PD-L1 therapy	10
Proteomic analysis of plasma exosomes in patients with non-small cell lung cancer	10
A large-scale, multicentered trial evaluating the sensitivity and specificity of digital PCR versus ARMS-PCR for detecting ctDNA-based EGFR p.T790M in non-small-cell lung cancer patients	10
A narrative review of evolving roles of radiotherapy in advanced non-small cell lung cancer: from palliative care to active player	10
Targeted therapies for KRAS-mutant non-small cell lung cancer: from preclinical studies to clinical development—a narrative review	10
Overdiagnosis in lung cancer screening	10
Prognostic significance of cribriform adenocarcinoma of the lung: validation analysis of 1,057 Japanese patients with resected lung adenocarcinoma and a review of the literature	10
Perioperative and long-term outcomes of spontaneous ventilation video-assisted thoracoscopic surgery for non-small cell lung cancer	10
Detection of epidermal growth factor receptor (EGFR) mutations from preoperative circulating tumor DNA (ctDNA) as a prognostic predictor for stage I–III non-small cell lung cancer (NSCLC) patients wit	10
The multiple roles and therapeutic potential of clusterin in non-small-cell lung cancer: a narrative review	10
Totality outcome of afatinib sequential treatment in patients with EGFR mutation-positive non-small cell lung cancer in South Korea (TOAST): Korean Cancer Study Group (KCSG) LU-19-22	10
Immune checkpoint inhibitors in elderly patients treated for a lung cancer: a narrative review	9
Segmental resection is associated with decreased survival in patients with stage IA non-small cell lung cancer with a tumor size of 21–30 mm	9
Correlation of tumor microenvironment-related markers with clinical outcomes in patients with squamous cell carcinoma of the lung	9
Systematic review of stereotactic body radiotherapy in stage III non-small cell lung cancer	9
Tubeless video-assisted thoracic surgery for pulmonary ground-glass nodules: expert consensus and protocol (Guangzhou)	9
Lung cancer screening: who pays? who receives?—the Chinese perspective	9
Prophylactic cranial irradiation in SCLC	9
Identification of PD-1 ligands: PD-L1 and PD-L2 on macrophages in lung cancer milieu by flow cytometry	9
Real-world experience of afatinib as first-line therapy for advanced EGFR mutation-positive non-small cell lung cancer in Korea	9
Local ablative therapies in oligometastatic NSCLC-upfront or outback?—a narrative review	9
An overview of the published and running randomized phase 3 clinical results of radiotherapy in combination with immunotherapy	9
Alternative methods for local ablation—interventional pulmonology: a narrative review	9
Titin mutation in circulatory tumor DNA is associated with efficacy to immune checkpoint blockade in advanced non-small cell lung cancer	9
The presence of lepidic and micropapillary/solid pathological patterns as minor components has prognostic value in patients with intermediate-grade invasive lung adenocarcinoma	9
Are polygenic risk scores ready for the cancer clinic?—a perspective	9
Immunotherapy in small cell lung cancer: one step at a time: a narrative review	9
How to optimize the incorporation of immunotherapy in trials for oligometastatic non-small cell lung cancer: a narrative review	9
A narrative review of deep learning applications in lung cancer research: from screening to prognostication	9
A nomogram for preoperative prediction of prolonged air leak after pulmonary malignancy resection	9
Preoperative systemic immune-inflammation index predicts survival and recurrence in patients with resected primary pulmonary sarcomatoid carcinoma	9
A narrative review of combined stereotactic ablative radiotherapy and immunotherapy in metastatic non-small cell lung cancer	9
EPAC-lung: European pooled analysis of the prognostic value of circulating tumour cells in small cell lung cancer	9
Lung cancer screening: who pays? Who receives? The European perspectives	9
Derivation and validation of a nomogram model for pulmonary thromboembolism in patients undergoing lung cancer surgery	9
A narrative review of the migration and invasion features of non-small cell lung cancer cells upon xenobiotic exposure: insights from in vitro studies	9
Cell-free DNA from cerebrospinal fluid can be used to detect the EGFR mutation status of lung adenocarcinoma patients with central nervous system metastasis	9
Risk-based prediction model for selecting eligible population for lung cancer screening among ever smokers in Korea	9
Assessment of the fear of COVID-19 and its impact on lung cancer screening participation among the Korean general population	9
Macrophages-based immune-related risk score model for relapse prediction in stage I–III non-small cell lung cancer assessed by multiplex immunofluorescence	8
Mobile 3-dimensional (3D) C-arm system-assisted transbronchial biopsy and ablation for ground-glass opacity pulmonary nodules: a case report	8
Cyclin-dependent kinase 4 upregulation mediates acquired resistance of dabrafenib plus trametinib in BRAF V600E-mutated lung cancer	8
Liquid biopsy in non-small cell lung cancer—current status and future outlook—a narrative review	8